Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
|Videos|December 15, 2020
Overview of the PIONEER Clinical Trial Program for Oral Semaglutide
Results from the PIONEER clinical trials program indicate that the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA), oral semaglutide, provides effective glycemic control across a range of different patient populations.
Click PLAY to watch the video abstract.
Click
Click
Related to this article
In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5